SynthesisDigestive diseases and sciences2026
Systematic Mapping of Worldwide Research on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Synthesis in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- FBP1-Mediated Compartmentalization of Glycolytic Enzyme Complexes Suppresses PKM2 Function to Ameliorate MASLD Progression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Bixin and Montelukast Combination Mitigates the Progression of MASLD to Cytokine-Driven Inflammatory Stress in an In Vitro Fluid-Dynamic Model.ACS omega · 2026Article
- Immune Determinants of MASLD Progression: From Immunometabolic Reprogramming to Fibrotic Transformation.Biology · 2026Review
- Impact of probiotics and prebiotics on glucose/lipid metabolism in metabolic dysfunction-associated steatotic liver disease: mechanisms and implications.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsMetabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide, affecting up to 38% of adults and nearly two-thirds of patients with type 2 diabetes, of whom one-third develop metabolic dysfunction-associated steatohepatitis (MASH). Although only a minority progress to cirrhosis or hepatocellular carcinoma, the absolute burden is substantial and continues to rise, particularly in Asia and Latin America. While population-level disparities are well documented, little is known about inequities within the scientific literature itself. We aimed to systematically map global MASLD/MASH research to identify patterns in productivity, geographic distribution, authorship, and disparities.
methodsWe analyzed publications from 1980 to 2024 in the Web of Science Core Collection (extraction May 15, 2025). After excluding meeting abstracts, 36,268 records were included. Using the Bibliometrix R package, we evaluated annual production, country and institutional contributions, authorship patterns, and journal sources. Disparity analyses focused on the 1000 most cited articles, assessing country contributions, first-author sex, and journal representation.
resultsAnalysis of the 1000 most cited MASLD/MASH publications revealed rapid growth since the early 2000s, peaking at over 60 papers annually between 2010 and 2020, with an apparent recent decline due to citation lag. The United States dominated both output and citations, far surpassing other countries. Hepatology, Journal of Hepatology, and Gastroenterology accounted for most influential publications. Leading contributors included two authors, with 50 articles each. Striking gender disparities emerged: only 3% of top 100 papers had female first authors. Overall, research remains concentrated geographically, institutionally, and by author, with persistent inequities in authorship representation.
conclusionsMASLD/MASH research is highly concentrated by geography, journals, and authorship, with pronounced gender disparities. Expanding inclusivity and fostering international collaborations are essential to advance this field.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.